Ethionamide
Ethionamide structure
|
Common Name | Ethionamide | ||
|---|---|---|---|---|
| CAS Number | 536-33-4 | Molecular Weight | 166.24300 | |
| Density | 1.17 g/cm3 | Boiling Point | 167 °C / 1mmHg | |
| Molecular Formula | C8H10N2S | Melting Point | 164 °C | |
| MSDS | USA | Flash Point | 133.2ºC | |
| Symbol |
GHS07, GHS08 |
Signal Word | Warning | |
|
The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents.
Antimicrob. Agents Chemother. 59(3) , 1534-41, (2015) Previous studies indicated that inhibition of efflux pumps augments tuberculosis therapy. In this study, we used timcodar (formerly VX-853) to determine if this efflux pump inhibitor could increase the potency of antituberculosis (anti-TB) drugs against Mycob... |
|
|
Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry.
J. Pharm. Biomed. Anal. 102 , 9-16, (2014) A simple and accurate liquid chromatography (LC)-tandem mass spectrometry (MS/MS) method for the quantitation of 20 anti-tuberculosis (anti-TB) drugs in human plasma, was developed as a tool for therapeutic drug monitoring. Two protein precipitation methods w... |
|
|
Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein.
Antimicrob. Agents Chemother. 58(6) , 3168-76, (2014) Predicting drug-drug interactions (DDIs) related to cytochrome P450 (CYP), such as CYP3A4 and one of the major drug transporters, P-glycoprotein (P-gp), is crucial in the development of future chemotherapeutic regimens to treat tuberculosis (TB) and TB/AIDS c... |
|
|
Bacteriological characterization of a Mycobacterium parascrofulaceum strain isolated from a Chinese pneumonia patient.
Int. J. Infect. Dis. 25 , 82-7, (2014) A Mycobacterium parascrofulaceum strain was isolated from a pneumonia patient-the first such reported case from China. The bacteriological characteristics of the strain were determined.Species identification was performed by homologue gene sequence comparison... |
|
|
Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region.
PLoS ONE 8(2) , e55299, (2013) India with a major burden of multidrug-resistant tuberculosis (MDR-TB) does not have national level data on this hazardous disease. Since 2006, emergence of extensively drug-resistant TB (XDR-TB) is considered a serious threat to global TB control. This study... |
|
|
Inhibitory Potential of Twenty Five Anti-tuberculosis Drugs on CYP Activities in Human Liver Microsomes.
Biol. Pharm. Bull. 38 , 1425-9, (2015) The direct inhibitory potential of twenty five anti-tuberculosis drugs on eight CYP-specific reactions in human liver microsomes was investigated to predict in vivo drug-drug interactions (DDIs) from in vitro data. Rifampicin, rifabutin, and thioacetazone inh... |
|
|
Fluoroquinolone-resistant tuberculosis at a medical centre in Taiwan, 2005-10.
J. Antimicrob. Chemother. 66(10) , 2437-8, (2011)
|
|
|
Abnormal thyroid function tests in children on ethionamide treatment.
Int. J. Tuberc. Lung Dis. 15(9) , 1191-3, i, (2011) Ethionamide (ETH) treatment may cause hypothyroidism. Clinical data, serum thyroid stimulating hormone (TSH) and free thyroxine (fT4) levels were retrospectively assessed in 137 children receiving anti-tuberculosis treatment including ETH. Abnormal thyroid fu... |
|
|
Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs.
J. Infect. Dis. 210(3) , 456-66, (2014) Drug tolerance likely represents an important barrier to tuberculosis treatment shortening. We previously implicated the Mycobacterium tuberculosis efflux pump Rv1258c as mediating macrophage-induced tolerance to rifampicin and intracellular growth. In this s... |
|
|
Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis.
Microb. Cell Fact. 14 , 82, (2015) Getting access to authentic human drug metabolites is an important issue during the drug discovery and development process. Employing recombinant microorganisms as whole-cell biocatalysts constitutes an elegant alternative to organic synthesis to produce thes... |